Georgia Life Sciences Association Statement on the Release of the NSCEB Final Report and Action Plan

Emerging biotechnology is key for U.S. to remain dominant and secure future economic growth in a new era of global competition

Georgia Life Sciences (GLS) applauds the National Security Commission on Emerging Biotechnology (NSCEB) for its leadership and vision in publishing its final report and action plan to Congress. This comprehensive roadmap is a vital step toward securing and advancing U.S. leadership in biotechnology at a critical moment for our nation's competitiveness, security, and economic future.


We strongly support the Commission’s call for urgent federal action, including the proposed $15 billion in new investments over five years, to ensure the U.S. biotechnology sector remains the global leader in innovation and commercialization. These resources will help drive transformative advances across healthcare, manufacturing, national security, and more.


The timing of this report is especially critical as our nation’s life sciences research and innovation infrastructure, particularly at the National Institutes of Health (NIH) and the Food and Drug Administration (FDA), faces considerable uncertainty. Strong federal leadership and investment are essential to maintain the momentum of discovery, innovation, and public health progress.


The report’s 49 recommendations, organized across six strategic pillars, offer a bold and actionable framework:

  • Prioritize biotechnology at the national level
  • Mobilize the private sector to get U.S. products to scale
  • Maximize the benefits of biotechnology for defense
  • Out-innovate our strategic competitors
  • Build the biotechnology workforce of the future
  • Mobilize the collective strengths of our allies and partners


Georgia Life Sciences encourages members of the Georgia congressional delegation to endorse the Commission’s report and advocate for its swift and full implementation by the administration. Georgia's leadership in life sciences innovation positions our state to be a key contributor in realizing the report’s vision, and federal support is essential to maximizing this opportunity for both regional and national impact.


As Georgia continues to grow its vibrant life sciences ecosystem, we recognize the immense potential of a coordinated national strategy to accelerate innovation, empower our workforce, and foster public-private partnerships. We look forward to working with policymakers, industry partners, and research institutions to implement these recommendations and deliver biotechnology solutions that improve lives and strengthen our country. As the report states, without this type of transformational investment, our adversaries will work to leverage their biotech advancements to attack, destroy, starve, and harm the U.S.


The full text of the final report can be found here: https://biotech.senate.gov 

Announcement: https://www.biotech.senate.gov/press-releases/nsceb-publishes-final-report/

BIO's statement is here.

Investing in America’s Biopharmaceutical Infrastructure Strengthens the Economy and Supports Union Workers

By Maria Thacker Goethe • December 20, 2025
The biopharmaceutical industry is growing America’s manufacturing and R&D capabilities to develop the next generation of treatments. A recent study from PILMA quantified the impact of the industry’s investment in American infrastructure on the economy and union workforce across 18 states from 2019-2024. The study found that across the 18 states included, the biopharmaceutical industry: Supported the American economy by investing $86.5B in R&D and manufacturing infrastructure and developing 1000+ construction projects at over 700 distinct facilities. Strengthened the American workforce by generating $2.6B in skilled union wages and providing $19M in support for union apprenticeships. The impact of the biopharmaceutical industry’s investment in American manufacturing and union jobs extends beyond direct benefits, spurring additional economic activity in the communities where workers live. This is known as the multiplier effect . On average, every $1 of new investment in a U.S. biopharmaceutical manufacturing facilities generates an additional $1.59 in further economic activity (2.59x times the initial investment value). The industry’s $86.5B investment in R&D and manufacturing infrastructure has a total economic impact of $224B. Check out this resource to learn more about how biopharmaceutical investment in American infrastructure supports America’s workers and communities. For more on how biopharmaceutical companies are investing in America’s future, visit innovation.org/america-investment .

Georgia Life Sciences Joins National Coalition Urging Congressional Action on Key Innovation Policies

December 10, 2025
Georgia Life Sciences has joined 43 state and regional life sciences organizations in signing a national Council of State Bioscience Associations (CSBA) letter calling on Congress to take immediate action on three bipartisan policy priorities that are essential to sustaining U.S. leadership in biomedical innovation and supporting patients nationwide. With Congress back in session and several critical programs at risk of expiring, the letter urges congressional leaders to advance the following provisions without delay: 1. Reauthorize the Rare Pediatric Disease Priority Review Voucher (PPRV) Program The PPRV program has been instrumental in incentivizing the development of therapies for children with rare and life-threatening conditions. Its lapse threatens to slow or halt research that families across the country are counting on. 2. Extend the SBIR/STTR Programs The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs provide crucial early-stage capital for emerging biotech and medtech companies—many of them in Georgia. Without reauthorization, hundreds of innovative small businesses face uncertainty, jeopardizing new therapies, diagnostics, and technologies in the pipeline, 3. Advance PBM Transparency Reforms Greater transparency and accountability within pharmacy benefit manager (PBM) practices are needed to ensure that savings reach patients and employers. Reforming PBM operations is essential to strengthening access and affordability across the healthcare system. A Unified Message from the Life Sciences Community The sign-on letter reflects broad, bipartisan alignment across the national life sciences ecosystem: researchers, entrepreneurs, investors, patient advocates, and state associations all share a common message— these programs underpin America’s global competitiveness and are vital to patients who rely on continued scientific progress. Georgia Life Sciences has shared the letter with members of Georgia’s congressional delegation and will continue engaging with policymakers to emphasize the importance of swift action.

GLS Joins Georgia Partners in Calling for Federal PBM Reform

December 7, 2025
Georgia Life Sciences is proud to stand with patient advocates, providers, and employers across the state in urging Congress to take meaningful action on pharmacy benefit manager (PBM) reform. We recently signed on to a joint letter to Georgia’s Congressional Delegation stressing the urgent need for transparency, fair practices, and policies that ensure savings flow directly to patients.
MORE POSTS